menu
    • menu
    [{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"RTX-003","moa":"CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"RubrYc Therapeutics \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc Therapeutics \/ iBio"},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"RTX-003","moa":"CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RubrYc Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by RubrYc Therapeutics

    Menu

    RubrYc Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RubrYc Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            RubrYc Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RTX-003

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : iBio

                            Deal Size : $6.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

                            Details : RTX-003 is a targeted anti-CD25 monoclonal antibody that binds CD25 without blocking IL-2 on the high-affinity IL-2 receptor alpha on T regulatory (T reg) cells, and designed to induce T reg cell death, thus supporting tumor immunity.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $1.0 million

                            September 21, 2022

                            Lead Product(s) : RTX-003

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : iBio

                            Deal Size : $6.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RubrYc Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            RubrYc Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RTX-003

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RubrYc Therapeutics To Present at AACR Virtual Conference

                            Details : The company will present discovery and pre-clinical data from their lead program RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells (Tregs) in the tumor microenvironment (TME) at the AACR Virtual Conference.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : RTX-003

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth